00

Shenzhen Hepalink Pharmaceutical Group Co LtdSHE 002399 Stock Report

Last reporting period 30 Jun, 2024

Updated 18 Sep, 2024

Last price

Market cap $B

1.71

Small

Exchange

XSHE - Shenzhen Stock Exchange

002399.SZ Stock Analysis

00

Uncovered

Shenzhen Hepalink Pharmaceutical Group Co Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

2/100

Low score

Market cap $B

1.71

Dividend yield

1.18 %

Shares outstanding

1 467.3 B

Shenzhen Hepalink Pharmaceutical Group Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Shenzhen, Guangdong and currently employs 2,046 full-time employees. The company went IPO on 2010-05-06. Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based pharmaceutical company focused on the field of heparin sodium preparations and raw materials, macromolecular drugs contract development manufacturing organization (CDMO) and innovative drug development. The Company’s main products and services include enoxaparin sodium preparations and heparin sodium bulk medicines, enoxaparin sodium bulk medicines, and CDMO services for macromolecular drugs. The firm distributes its products within the domestic market and to overseas markets, including Turkey, Brazil, the United States and others.

View Section: Eyestock Rating